Rupal Oquinn News Today

Fewer patients with chronic lymphocytic leukemia experienced cardiac toxicities with Calquence than those treated with Imbruvica, research showed.

Administration of acalabrutinib to patients with chronic lymphocytic leukemia with or without cardiovascular disorders at baseline results in a numerically decreased incidence of overall treatment-related cardiac toxicities and a comparable safety profile vs comparator CLL therapies such as ibrutinib.